Clinical trial NCT04504604: TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Official title: TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rare Cancers
Cholangiocarcinoma
Cancer of Unknown Primary Site
Keywords: genomics
precision medicine
molecular tumor board
remote participation
targeted therapy
patient reported outcomes
understudied diseases
comprehensive genomic profiling
virtual
next generation sequencing
liquid biopsies
tumor biopsies
cell-free DNA
biomarker testing
solid tumors
Lead sponsor: TargetCancer Foundation
Sponsor class: OTHER
Collaborators: name: Foundation Medicine
First posted: 2020-08-07
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: DIAGNOSTIC

Brief summary: This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Detailed description: This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results. The study leverages a remote consent and participation approach to open enrollment to all patients with rare tumors within the United States. Traditional, site-based patient consenting and participation is also available for enrollment to the study.

Each participant will undergo comprehensive genomic profiling (CGP) by Foundation Medicine Inc. (FMI) of their tumor as well as plasma circulating cell-free DNA. Plasma circulating cell-free DNA may be additionally collected for repeat CGP at various timepoints during the study.

The CGP findings will be provided by FMI directly to the treating physician and study sponsor TargetCancer Foundation (TCF), with TCF presenting cases with genomic findings to the Virtual Molecular Tumor Board (VMTB). The VMTB will analyze the findings and provide a written report to the treating physician on recommended treatments and/or relevant clinical trials; the treating physician makes all treatment decisions. The resultant treatments and treatment responses will be tracked longitudinally during the term of this study, thus linking molecularly informed treatments to specific patient outcomes.

Eligibility criteria: INCLUSION CRITERIA

* Provision of signed and dated informed consent form.
* Stated willingness to comply with all study related blood draws and assessments for the duration of the study.
* Individuals who are 18 years old or older at the time of consent.
* Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.
* May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
* Willingness to provide existing archived and/or newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.
* For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
* Willingness to provide clinical and medical information to the study team as required.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
* Ability to read, write and communicate in English.
* Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.
* Resides within the United States.

EXCLUSION CRITERIA

* Participants who are unable to provide informed consent.
* Participants who are 17 years of age or younger.
* Participants who are unable to comply with the study procedures.
* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
* Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.
* Pregnancy or breastfeeding.
* Any unlisted criteria at the discretion of the treating physician.

Primary outcomes:
measure: Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.
timeFrame: 2 years
measure: Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.
timeFrame: 2 years
Secondary outcomes:
measure: Comparison of Tumor Biomarker Profiling to Treatment Outcome.
timeFrame: 2 years
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: TargetCancer Foundation
state: Massachusetts
Study officials:
affiliation: Medical College of Wisconsin
name: Razelle Kurzrock, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: SCRI Development Innovations, LLC
name: Vivek Subbiah, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Diego
name: Shumei Kato, M.D.
role: PRINCIPAL_INVESTIGATOR
References: